Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma.
Fiche publication
Date publication
avril 2017
Journal
Journal of the National Cancer Institute
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BORG Christophe, Pr BOUCHE Olivier, Dr FEIN Francine, Pr HEYD Bruno, Dr VIENOT Angélique, Dr LAKKIS Zaher
Tous les auteurs :
Vienot A, Beinse G, Louvet C, de Mestier L, Meurisse A, Fein F, Heyd B, Cleau D, d'Engremont C, Dupont-Gossart AC, Lakkis Z, Tournigand C, Bouché O, Rousseau B, Neuzillet C, Bonnetain F, Borg C, Vernerey D
Lien Pubmed
Résumé
In advanced pancreatic ductal adenocarcinoma (aPDAC), there is no consensual strategy for second-line chemotherapy (L2). Better discrimination of overall survival (OS) may help clinical decision-making. We aimed to predict OS from the beginning of L2 and to assess the benefit from chemotherapy among the identified risk groups.
Mots clés
Age Factors, Aged, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Ascites, etiology, Camptothecin, administration & dosage, Cancer Pain, etiology, Carcinoma, Pancreatic Ductal, drug therapy, Deoxycytidine, administration & dosage, Disease-Free Survival, Female, Fluorouracil, administration & dosage, Health Status, Humans, Irinotecan, Jaundice, etiology, Liver Neoplasms, secondary, Male, Middle Aged, Multivariate Analysis, Nomograms, Organoplatinum Compounds, administration & dosage, Oxaliplatin, Pancreatic Neoplasms, drug therapy, Proportional Hazards Models, Prospective Studies, Retreatment, Risk Factors, Smoking, Survival Rate
Référence
J. Natl. Cancer Inst.. 2017 Apr;: